FORT WORTH, Texas, April 20, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today released a letter from its president, Deborah Jenkins Hutchinson to update the shareholders on the current status of the company.
April 20, 2011
Dear Wound Management Technologies Shareholder,
I'm writing to inform you that our Company has entered an exciting new chapter in its development and to provide you with details on a number of initiatives that we believe will favorably impact our business in 2011.
When I joined Wound Management in January of 2010, my primary challenge was to develop a sales engine for our existing line of wound treatment products. I am pleased to tell you that Wound Management Technologies' (WNDM) 2010 revenues were over three times 2009 revenues and that the commercialization plan that we initiated last year is gaining traction. Our CellerateRX® activated collagen wound care product line sales have increased both in the United States and international markets. Furthermore, in January of this year we forecast $6M in revenues for 2011, an increase of over six times 2010, and we believe we will meet or exceed that number. WNDM is now rapidly emerging and we believe that we will be both cash flow positive and profitable in the upcoming 12-18 months. You can find further details about our operational progress in the company's 2010 Form-10K filed on April 14, 2011.
One of our challenges in 2010 was to secure adequate financing for inventory to meet anticipated product order growth. That process took a few months longer than we hoped, but we were able to raise the $2 - $3M that we discussed in last year’s letter in increments. We received inventory in the 4th Quarter and have ordered more since. Those small financings and some business transactions have given us the ability to more aggressively market the CellerateRX® products.
CellerateRX® Activated Collagen™
CellerateRX® targets a multi-billion dollar domestic and international wound care market with over 60% profit margins. A large part of the growth in the wound care markets is from diabetic ulcers. The advanced wound care market is over $5B worldwide now and forecasts show that by 2025 just the Global Diabetic Market could have in excess of 48 million patients that could be a candidate for CellerateRX®.
CellerateRX®'s activated collagen (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to prepare the collagen for use in the wound healing process. In people with compromised health or circulation, the difference in wound healing can be significant. You can read through numerous evidence-based studies on the www.celleraterx.com website.
CellerateRX® is FDA cleared for all wound types except for 3rd degree burns and is available in both powder and gel form. The products have HCPC codes for reimbursement by Medicare and other insurers. In addition to being used in healthcare settings throughout the country, CellerateRX® is easily applied by patients by themselves at home. CellerateRX® is safe, non-toxic, and easy to use. Wound Care Innovations, LLC (WCI), a wholly owned subsidiary of WNDM, has the exclusive worldwide licensing and distribution rights for CellerateRX® advanced wound care collagen products.
New Product Pipeline
While we have been commercializing the CellerateRX® business we have also been strategically planning the market launch of products in our pipeline from our Resorbable Orthopedic Products (ROP) subsidiary and our Secure eHealth subsidiary. ROP plans to file 510ks for resorbable bone wax and bone void filler products in the next few weeks. Secure eHealth and its secure healthcare communications tools were featured in the Interoperability Showcase at the Health Information Systems Society meeting in February 2011 in Orlando. Look for more about both of these on our website and in our news.
Here is a brief recap of some key items over the past year:
Sales & Marketing Initiatives
WNDM in the Press
CellerateRX® is gaining respect in the medical community and in the press. You can learn about recent exposure on our websites and on our You Tube channels (just click the You Tube icon from www.wmgtech.com or www.celleraterx.com ). Among "new" news is:
Investor Relations / News / Reports
Over the past year WNDM has spoken at numerous investment conferences and meetings to educate investors about WNDM and our growth. We have spoken at Undiscovered Equities Conferences, NIBA (the National Investment Banker's Association), LifeTech Capital's Miami Medical Investors Conference, OneMedForum, and the National Eagles and Angels Association (NEAA). This has led to Independent Research reports about us – one from Mithra in the summer of 2010 and one from NEAA last week.
Our 18 Month Value Growth Milestones – announced in January 2011
Stay In Touch With Us
If you aren’t getting copies of our press releases, customer newsletters and corporate news events, opt-in on our websites for the mail list. You will automatically be notified when something major occurs and you can receive copies of the quarterly CellerateRX® Newsletter.
As you can see, a lot has happened in the past year. We have entered a new chapter in our history as we move towards profitability and growing market share. More and more people know about WNDM and about CellerateRX®. The distribution and marketing channels in the US and internationally continue to expand because our products uniquely fill a need in the growing advanced wound care market. At the same time, we are also working on our product pipeline initiatives to add enhanced value in the future. We are focused on making Wound Management Technologies a strong healthcare company for our customers, our employees and our shareholders.
Deborah Jenkins Hutchinson
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved